Omeros drug fails a PhIII kidney trial, stock nearly halved
The late-stage flop in immunoglobulin A nephropathy, or IgAN, is a blow to Omeros’ pipeline-in-a-product plans for narsoplimab.
Omeros will end the ARTEMIS-IGAN study, given it missed the mark in the IgA nephropathy trial, which failed to reach statistical significance on reducing more elevated protein in urine than placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.